Use of Von Hippel-Lindau (VHL) as a marker to identify cancer patients responsive to Src kinase inhibitors
OHSU # 1643
Targeted therapies are effective in treating homogeneous cancers driven by a single activating oncogene. However, they are much less effective at treating molecularly heterogeneous cancers, such as metastatic Renal Cell Carcinoma (RCC). Thus, there is an ongoing need to identify cancer biomarkers that can be used to determine appropriate and effective treatment regimens for molecularly complex malignant diseases.
This technology is a personalized medicine approach to stratify cancer patients with Von Hippel-Lindau (VHL)-positive cancer who may benefit from treatment with Src kinase inhibitors. More specifically, the technology is a diagnostic test that measures the expression of VHL, relative to a predetermined VHL threshold level of expression. The expression level of VHL also can be measured in combination with the expression level of one or more of Src kinase, carbonic anhydrase 9 (CA-IX), phosphorylated focal Adhesion Kinaase (FAK), Protein Tyrosine Phosphatase (PTP)1B, Hypoxia Inducible Factor (HIF)-1 and/or HIF-2.
Sci. Transl. Med. 2011 Jun 1; 3(85): 85ra47
- George Thomas, SM.Knight Prostate Program
For more information, contact:
Technology Development Manager